ANTX

AN2 Therapeutics Inc

Mar 19 • 04:00PM ET

3.91

-0.71 -15.37 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX PFE GILD VRTX REGN BMRN ALNY BIIB

Index	-	P/E	-	EPS (ttm)	-1.16	Insider Own	43.45%	Shs Outstand	27.41M	Perf Week	-28.12%
Market Cap	140.53M	Forward P/E	-	EPS next Y	-	Insider Trans	-0.45%	Shs Float	15.50M	Perf Month	279.61%
Enterprise Value	82.53M	PEG	-	EPS next Q	-	Inst Own	38.20%	Short Float	0.38%	Perf Quarter	237.07%
Income	-35.17M	P/S	-	EPS this Y	-	Inst Trans	1.48%	Short Ratio	0.04	Perf Half Y	203.10%
Sales	0.00M	P/B	2.02	EPS next Y	-	ROA	-45.67%	Short Interest	0.06M	Perf YTD	242.98%
Book/sh	1.94	P/C	2.42	EPS next 5Y	-	ROE	-52.14%	52W High	6.91 -43.41%	Perf Year	167.81%
Cash/sh	1.61	P/FCF	-	EPS past 3/5Y	19.17% -8.39%	ROIC	-66.29%	52W Low	1.00 291.00%	Perf 3Y	-55.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.97% 23.33%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	32.36%	Oper. Margin	-	ATR (14)	0.65	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.87	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	59.88	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.87	EPS Q/Q	-13.98%	SMA20	33.02%	Beta	-1.56	Target Price	1.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	109.71%	Rel Volume	0.51	Prev Close	4.62
Employees	21	LT Debt/Eq	0.00	Earnings	Mar 17 AMC	SMA200	194.77%	Avg Volume	1.35M	Price	3.91
IPO	Mar 25, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	-20.83% -	Trades		Volume	690,257	Change	-15.37%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-09-24	Downgrade	Leerink Partners	Outperform → Market Perform	$5 → $1
Aug-09-24	Downgrade	Evercore ISI	In-line → Underperform
Jul-03-24	Upgrade	Leerink Partners	Market Perform → Outperform	$5
Apr-02-24	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$6
Feb-13-24	Downgrade	Leerink Partners	Outperform → Market Perform	$23 → $7
Feb-12-24	Downgrade	Oppenheimer	Outperform → Perform
Feb-12-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Feb-12-24	Downgrade	Evercore ISI	Outperform → In-line	$25 → $7
Jan-04-24	Initiated	JMP Securities	Mkt Outperform	$30
Jul-18-22	Resumed	Oppenheimer	Outperform	$22

Mar-17-26 04:00PM	AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights (Business Wire) +6.61% -7.60%
Mar-09-26 02:49PM	AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? (Benzinga) +84.21%
07:00AM	AN2 Therapeutics Announces $40 Million Private Placement Financing (Business Wire)
Mar-03-26 04:00PM	AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) (Business Wire) +26.42%
Feb-17-26 07:00AM	AN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare Conference (Business Wire)
07:00AM	Loading…
Jan-12-26 07:00AM	AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease (Business Wire) -12.31%
Jan-09-26 12:00PM	AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? (Zacks)
Nov-12-25 04:01PM	AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights (Business Wire)
Nov-10-25 07:00AM	AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB) (Business Wire)
Nov-06-25 05:03PM	AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference (Business Wire)
Aug-12-25 04:01PM	AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights (Business Wire)
07:00AM	AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease (Business Wire)
Jul-23-25 07:00AM	AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease (Business Wire)
Jun-30-25 07:00AM	AN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of Epetraborole (Business Wire)
07:00AM	Loading…
May-29-25 07:00AM	AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference (Business Wire) +5.22%
May-13-25 04:01PM	AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights (Business Wire)
May-01-25 04:00PM	AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline (Business Wire)
Apr-30-25 07:00AM	AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference (Business Wire)
Mar-25-25 04:00PM	AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights (Business Wire)
Mar-03-25 04:00PM	AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference (Business Wire)
Feb-24-25 07:00AM	AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease (Business Wire)
Feb-20-25 07:00AM	AN2 Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Jan-29-25 04:00PM	AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Nov-14-24 07:00AM	AN2 Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Nov-13-24 04:00PM	AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline (Business Wire)
Oct-17-24 07:00AM	AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria (Business Wire)
Aug-28-24 04:00PM	AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-19-24 10:29AM	AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why (Zacks) +7.14%
Aug-16-24 07:00AM	AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan (Business Wire)
04:01PM	Loading…
Aug-13-24 04:01PM	AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights (Business Wire) +5.83%
Aug-09-24 12:15PM	Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce (Benzinga) -60.98%
09:33AM	AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial (Pharmaceutical Technology)
Aug-08-24 04:30PM	AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease (Business Wire) +6.88%
Jul-03-24 09:50AM	Intuit initiated, Charter downgraded: Wall Street's top analyst calls (The Fly) +27.23%
May-21-24 09:35AM	Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround (Zacks)
May-14-24 10:55PM	ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights (Business Wire)
Mar-28-24 11:53PM	ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q4 2023 (InvestorPlace) +15.69%
04:10PM	AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights (Business Wire)
Mar-22-24 07:00AM	Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results (PR Newswire)
Feb-22-24 04:21AM	13 Best Falling Stocks To Buy Right Now (Insider Monkey)
Feb-12-24 10:03AM	AN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire) -74.50%
07:04AM	UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment (Reuters)
06:54AM	AN2 Therapeutics to pause lung disease study enrollment (Reuters)
06:45AM	AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease (Business Wire)
Jan-30-24 04:10PM	AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference (Business Wire)
Jan-12-24 03:02AM	AN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 Shares (GuruFocus.com)
Jan-10-24 08:50AM	Recent Price Trend in AN2 Therapeutics, Inc. (ANTX) is Your Friend, Here's Why (Zacks)
Nov-09-23 04:05PM	AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights (Business Wire) -7.08%
Nov-06-23 08:50AM	AN2 Therapeutics, Inc. (ANTX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
07:00AM	AN2 Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Oct-18-23 07:00AM	AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease (Business Wire)
Oct-11-23 12:01AM	AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023 (Business Wire)
Sep-27-23 09:40AM	Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? (Zacks)
Sep-26-23 07:00AM	AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria (Business Wire) +11.26%
Sep-13-23 07:00AM	AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease (Business Wire) -5.58%
Sep-11-23 09:40AM	Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-15-23 10:42PM	AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock (Business Wire) +7.06%
Aug-10-23 04:10PM	AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights (Business Wire)
Jun-14-23 08:55AM	Companies Like AN2 Therapeutics (NASDAQ:ANTX) Are In A Position To Invest In Growth (Simply Wall St.)
May-25-23 04:10PM	AN2 Therapeutics to Present at Jefferies Healthcare Conference (Business Wire)
May-18-23 07:00AM	Eric Easom Spends US$54k On AN2 Therapeutics Stock \ (Simply Wall St.) -5.43%
May-11-23 04:10PM	AN2 Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights (Business Wire)
May-09-23 06:05AM	AN2 Therapeutics, Inc.'s (NASDAQ:ANTX) market cap dropped US$43m last week; individual investors who hold 33% were hit as were institutions (Simply Wall St.) -8.04%
May-01-23 07:00AM	AN2 Therapeutics to Present at JMP Securities Life Sciences Conference (Business Wire)
Mar-29-23 04:01PM	AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights (Business Wire)
Feb-28-23 04:10PM	AN2 Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Jan-31-23 04:10PM	AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference (Business Wire) +15.30%
Dec-04-22 08:40AM	AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-09-22 04:05PM	AN2 Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) -7.43%
Nov-02-22 04:10PM	AN2 Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +10.07% +6.41%
Oct-19-22 08:00AM	AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022 (GlobeNewswire) -8.38%
Oct-06-22 07:00AM	AN2 Therapeutics Provides Update on Epetraborole Ex-U.S. Development Plan in Treatment-Refractory MAC Lung Disease (GlobeNewswire)
Sep-29-22 07:00AM	NIH Awards Contract to AN2 Therapeutics Valued Up to $17.8 Million (GlobeNewswire) -7.21%
Aug-29-22 07:00AM	AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) -10.18%
Aug-11-22 04:10PM	AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +6.42% +64.66%
Aug-08-22 11:42AM	What Type Of Shareholders Make Up AN2 Therapeutics, Inc.'s (NASDAQ:ANTX) Share Registry? (Simply Wall St.)
Jul-01-22 10:39AM	Bay Area's stream of new public companies has slowed to a weak trickle (American City Business Journals) +5.29%
Jun-29-22 07:00AM	AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease (GlobeNewswire)
Jun-27-22 09:19AM	We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate (Simply Wall St.)
May-10-22 04:10PM	AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire) +6.88% +6.81%
May-09-22 07:00AM	AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors (Business Wire) -19.66%
Apr-18-22 09:30AM	Here are the Bay Area's biggest startup exits of the first quarter (American City Business Journals) +5.49%
Mar-28-22 10:33AM	Only 9 Bay Area companies went public in this quarter. Here's how they did. (American City Business Journals)
Mar-25-22 04:40PM	AN2 Therapeutics Rises in First Day of Trading (Barrons.com)
03:06PM	RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15 (Benzinga)
Mar-24-22 10:32PM	AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
02:11PM	AN2 Therapeutics Will Trade Friday. Now There Are 2 March IPOs. (Barrons.com)

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley and is headquartered in Menlo Park, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Williams Sarah Joanne	Principal Accounting Officer	Mar 03 '26	Sale	1.06	327	347	66,848	Mar 05 06:55 PM
Day Lucy	Chief Financial Officer	Jan 06 '26	Sale	1.01	5,512	5,578	75,363	Jan 07 08:15 PM
Day Lucy	Chief Financial Officer	Jan 05 '26	Sale	1.00	3,295	3,305	80,875	Jan 07 08:15 PM
Prior Stephen David	Chief Strategy Officer	Jan 05 '26	Sale	1.00	3,604	3,615	61,944	Jan 07 08:15 PM
Prior Stephen David	Chief Strategy Officer	Jan 06 '26	Sale	1.01	2,858	2,892	59,086	Jan 07 08:15 PM
Chanda Sanjay	Chief Development Officer	Jan 06 '26	Sale	1.01	5,956	6,027	75,823	Jan 07 08:13 PM
Chanda Sanjay	Chief Development Officer	Jan 05 '26	Sale	1.00	3,295	3,305	81,779	Jan 07 08:13 PM
Eizen Joshua M	See Remarks	Jan 05 '26	Sale	1.00	17,923	17,948	159,430	Jan 07 08:12 PM
Eizen Joshua M	See Remarks	Jan 06 '26	Sale	1.01	6,931	7,014	152,499	Jan 07 08:12 PM
Eizen Joshua M	See Remarks	Nov 04 '25	Sale	1.14	2,819	3,214	177,353	Nov 06 06:12 PM
Prior Stephen David	Chief Strategy Officer	Nov 04 '25	Sale	1.14	765	872	65,548	Nov 06 06:11 PM
Leonard Braden Michael	10% Owner	May 28 '25	Sale	1.09	200,000	218,000	3,017,432	Jun 16 03:40 PM
Easom Eric	Chief Executive Officer	Jun 02 '25	Buy	1.07	10,000	10,665	256,380	Jun 03 04:46 PM
Leonard Braden Michael	10% Owner	May 28 '25	Sale	1.16	2,100,000	2,436,000	3,649,432	May 30 05:40 PM
Leonard Braden Michael	10% Owner	May 30 '25	Sale	1.01	432,000	436,477	3,217,432	May 30 05:40 PM
FitzPatrick Margaret M	Director	May 28 '25	Buy	1.18	8,610	10,133	8,610	May 29 04:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANTX

AN2 Therapeutics Inc

Upgrade your FINVIZ experience